Insmed (NASDAQ: INSM) reported Q4 EPS of ($0.95), $0.05 worse than the analyst estimate of ($0.90). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $50.78 million.

For earnings history and earnings-related data on Insmed (INSM) click here.